Our company is a R&D driven biotechnology firm specializing in therapeutic and diagnostic seeds for pancreatic cancer. We are developing antibodies that target pancreatic cancer stem cells and products utilizing unique antibodies derived from pancreatic cancer patients. Dedicated to bringing early diagnostic tools and effective treatments for pancreatic cancer to patients as quickly as possible, our goal is to ensure that our drug seeds and innovative technologies make a significant contribution to the treatment and early detection of pancreatic cancer.
Development of cancer treatment equipment using optical electromagnetic waves
A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.
Integrated BioFoundry DBTL: BioFoundry (ultrahigh-speed microbial breeding) DBTL: Elementary technology utilization Scale-up process development In-house product development Intestinal microbiome model
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.